For laboratory research use only. Not for human or veterinary use. Read our research-use policy

GLP-1 research

Survodutide research peptide

A peptide that agonises both the glucagon receptor and the GLP-1 receptor.

1 size · from $69.99 · 0 in stock · flat $24.95 US shipping per order

Sizes, prices and availability

Survodutide sizes and prices
SizeSKUStated purityBatch COAPriceAvailability
10 mg SUR10 Not yet provided Not yet provided $69.99 Out of stock

Prices and stock are checked at build time and refreshed live in your browser. Orders are US only for a flat $24.95 shipping fee. Shipping details

About Survodutide

Survodutide is a dual agonist of the glucagon receptor and the GLP-1 receptor. A 2024 paper in Diabetes, Obesity and Metabolism describes the biomarkers and pharmacological profiling used to select it as a clinical candidate.

Compared with tirzepatide (GIP and GLP-1 receptors) and retatrutide (GIP, GLP-1 and glucagon receptors), survodutide sits between them in receptor coverage: it combines GLP-1 and glucagon receptor activity without GIP receptor activity.

What the published literature covers

  • Thomas et al. (2024) describe the pharmacological profiling and biomarkers behind selection of survodutide as a clinical candidate.
  • Phase 2 trial reports exist in obesity (The Lancet Diabetes & Endocrinology, le Roux et al., 2024) and in MASH with fibrosis (New England Journal of Medicine, Sanyal et al., 2024).

Vial arithmetic

The peptide reconstitution calculator converts a vial size, diluent volume and target amount into concentration, syringe units and draws per vial. Volumes convert to syringe units with the syringe units converter. It does arithmetic only and does not suggest any amount.

FAQ

Which receptors does survodutide act on?

Survodutide is a dual agonist of the glucagon receptor and the GLP-1 receptor.

What sizes of Survodutide does Covalume list?

Covalume lists Survodutide in one size: 10 mg. Each size shows its price and live stock status in the variants table on this page.

How is the purity of Survodutide documented?

Each listing shows the purity the supplier states, labelled (supplier), and the batch Certificate of Analysis field reads "Not yet provided" until a batch-specific document is on file. Our guide to reading a Certificate of Analysis explains what HPLC and mass-spectrometry results show.

References

  1. Thomas L, Martel E, Rist W, et al. (2024). The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection. Diabetes Obes Metab 26:2368-2378. PubMed 38560764 · DOI
  2. le Roux CW, Steen O, Lucas KJ, et al. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol 12:162-173. PubMed 38330987 · DOI
  3. Sanyal AJ, Bedossa P, Fraessdorf M, et al. (2024). A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med 391:311-319. PubMed 38847460 · DOI

Identity values are from PubChem (CID 171378821) and the cited papers; for linear peptides the mass was also checked against the sequence. Last updated 2026-11-18.

Related research peptides

From the research library